Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acerus Pharmaceuticals announced that the agreement with Endo Ventures Bermuda (an affiliate of Endo International plc) relating to the commercialization of Natesto in the US and Mexico will be terminated, effective 30 June 2016.
Subscribe to our email newsletter
Under the terms of the agreement with Acerus, Endo will continue to sell and distribute Natesto in the US until the effective date of termination.
Acerus president and CEO Tom Rossi said: "While we are disappointed with Endo’s previously announced strategic business decision to realign their U.S. branded resources from urology retail to their pain franchise, we are fully committed to the continued success of Natesto in the U.S.
"Our immediate focus is on finding a new Natesto partner in the U.S., the largest market for testosterone replacement therapy. We are encouraged by the positive physician and patient feedback received on the product to date, and believe there will be strong interest from other companies to step in and continue to drive the launch of Natesto."